ClinicalTrials.gg
Not yet recruitingNCT07945574Updated Nov 18, 2026

Cryotherapy for Bronchoscopic Management of Central Airway Obstruction: Clinical Experience at Assiut University Hospital.

An interventional study of Cryotherapy for Bronchoscopic Management of Central Airway Obstruction in Central Airway Obstruction, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Assiut University · Not applicable, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).

Read the detailed description

Introduction:

Central airway obstruction (CAO) is defined as significant narrowing of the trachea, main stem bronchi or the bronchus intermedius, and occurs in a wide variety of airway disorders, including endobronchial tumors, post-intubation and post-tracheostomy stenosis, post-infectious stenosis, granulation tissue, tracheomalacia, and foreign body obstruction . It is associated with a poor prognosis and impaired quality of life, even when the underlying cause is benign.

Therapeutic bronchoscopy can improve symptoms, quality of life, and survival in patients with CAO, and the current American College of Chest Physicians guideline supports a multimodality approach that includes tissue debridement, ablation, dilation, and stent placement according to the underlying disease . Recent evidence shows substantial improvements in breathlessness and quality of life after therapeutic airway interventions, with a low complication rate in a large long-term series.

Bronchoscopic cryotherapy is a pragmatic modality for recanalization of CAO that can be delivered through a flexible bronchoscope under moderate sedation, achieving more than partial airway patency in about 90% of sessions in an 11-year single-center cohort, although bleeding remains the main concern [7]. Its usefulness has also been shown in tumor-like endobronchial tuberculosis and, with the spray technique, in a prospective registry of central airway diseases . In Egypt, a single-center study reported that cryotherapy was safe and improved clinical scores, pulmonary function, and quality of life in patients with CAO of different etiologies . Evidence regarding bronchoscopic cryotherapy for CAO remains limited in our region despite its increasing clinical utilization. This study aims to assess the feasibility, safety, and clinical outcomes of bronchoscopic cryotherapy for CAO within the constraints of a resource-limited healthcare environment and evaluating our institutional experience at Assiut University Hospital.

  • The aim of this study is to evaluate the clinical efficacy of therapeutic bronchoscopic cryotherapy for management of central airway obstruction (CAO).
  • Type of the study: Prospective Interventional Study.
  • Study Group: The study will include patients diagnosed with central airway obstruction (CAO) and fit for bronchoscopy.
  • Study Setting: Respiratory bronchoscopy unit, Assuit University Hospital. Study subjects: All adult patients diagnosed with central airway obstruction(CAO) and fit for bronchoscopic intervention will be eligible.

    a. Inclusion criteria:

    • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy
    • b. Exclusion criteria:
    • Patients with coagulopathy (INR > 1.5).
    • Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
    • Severe pulmonary hypertension (PASP > 55 mmHg).
    • Hemodynamic instability.
    • Lung collapse > 2 months duration. c.Sample size calculation:

The sample size was calculated using Epi Info™️ version 7 software based on the following assumptions:

The primary outcome variable was the successful airway recanalization rate. Based on a previous study by Hussein et al. (2026), the overall successful recanalization rate (complete and partial) was 96%. Assuming an expected proportion of 96%, a confidence level of 90%, and a confidence limit (margin of error) of 5%, the minimum required sample size was estimated to be 42.

  • Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, …):

Baseline Evaluation

Prior to the intervention, all candidates will undergo:

  • Clinical Assessment: Detailed history taking, physical examination, and dyspnea assessment using the modified Medical Research Council (mMRC) scale, while cough and hemoptysis were evaluated using the Walsh cough score and the Morice hemoptysis severity score, respectively.
  • Laboratory Tests: CBC, liver/kidney functions, coagulation profile, fasting blood glucose, and Arterial Blood Gases (ABG)
  • Radiological Imaging: Plain Chest X-ray (PA view) and CT chest to evaluate the site and extent of the obstruction.
  • Functional assessment : ABG and pulmonary function test pre and post procedure. Intervention Protocol (Therapeutic Bronchoscopy)

    1. General Preparation

  • Anesthesia: This procedure will be performed under local anesthesia .
  • Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel.
  • Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine.
  • Mapping: Determination of the location and degree of obstruction according to the Freitag et al [8]. scheme.

    1. Specific Techniques

Bronchoscopic Cryotherapy (ERBOKRYO CA):

In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation.

  • Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C [9].
  • Application: Procedures will be conducted under local aesthesia in one or two sessions, each lasting 30-60 min. The cryo¬probe will be inserted through the bronchoscope biopsy channel which is positioned approximately 10 mm above the lesion and the probe is in direct contact to the lesion. The lesion will be frozen for 20-60 s/cycle for three cycles to devascularize the tumor, after which the bronchoscope and cryoprobe will be removed together with adherent tissue.

IV. Follow-up Parameters

  • Immediate (Post-procedure): Chest X-ray within 2 hours to exclude pneumothorax.
  • Short-term: Monitoring for peri-procedural complications within the first 24 hours Complications were classified as minor (e.g., self-limited bleeding, transient hypoxemia, mild pneumomediastinum not requiring invasive intervention) or major (e.g., life-threatening bleeding, respiratory failure requiring ventilatory support, pneumothorax requiring chest tube insertion).This classification was conceptually aligned with the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  • Bronchoscopic grading of bleeding severity; Grade 1: Bleeding requiring suctioning for less than 1 minute. Grade 2: Bleeding requiring suctioning for more than 1 minute, repeated wedging of the bronchoscope, or topical haemostatic agents.

Grade 3: Bleeding requiring selective intubation with an endotracheal tube or balloon/bronchial blocker for less than 20 minutes, or premature termination of the procedure.

Grade 4: Persistent selective intubation for more than 20 minutes, ICU admission, transfusion, bronchial artery embolisation, or resuscitation.

- Long-term: Patients will be followed for up to 3 months post-procedure, including:

  • Clinical evaluation ;

    - Quality of life (SF-36),symptoms(cough,dyspnea,hemoptysis).

  • Functional Evaluation ; ABG and spirometry.
  • Bronchoscopic evaluation (to check for re-obstruction)if clinically indicated.
  • Radiological evaluation (CT or Chest X-ray).

    • Research outcome measures:

      1. Primary (main):

Technical efficacy: Percentage of patients achieving successful airway recanalization following bronchoscopic cryotherapy, according to the Freitag et al \& Hussein et al :

  1. Complete canalization: ≥90% restoration of airway lumen
  2. Partial canalization: 50-89% restoration.
  3. Failed canalization: \<50% restoration or inability to proceed due to complications

b. Secondary (subsidiary):

  1. Symptomatic Improvement: Changes in dyspnea (mMRC scale),cough and hemoptysis score evaluated at short-term and at the 3-month follow-up.
  2. Safety Profile: incidence of minor and major peri-procedural complications within 24 hours, categorized using the Common Terminology Criteria for Adverse Events (CTCAE) framework.
  3. Long-term Airway Patency: Rate of re-obstruction and CAO-related re-hospitalization during the 3-month follow-up period.
  4. Overall Survival: Estimation of the 1-year overall survival (OS) rate post-intervention
02

Conditions studied

  • Central Airway Obstruction

Browse trials for

03

In context

Airway Obstruction

148 studies on the registry are indexed under Airway Obstruction; 26 are open to participants now.

This study's planned enrollment of 42 is below the median of 52 across 93 interventional studies indexed under Airway Obstruction.

Browse Airway Obstruction studies →

Lead sponsor

Assiut University is the lead sponsor of 5,092 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy.

Exclusion criteria

Exclusion Criteria:

  • Patients with coagulopathy ( > 1.5).
  • Severe hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia).
  • Severe pulmonary hypertension (PASP > 55 mmHg).
  • Hemodynamic instability.
  • Lung collapse > 2 months duration
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    All adult patients diagnosed with CAO and fit for bronchoscopic intervention

    Study subjects: All adult patients diagnosed with CAO and fit for bronchoscopic intervention will be eligible. a. Inclusion criteria: * Adult patients (above 18 years old) presenting with endobronchial lesions causing central airway obstruction. and fit for bronchoscopy * b. Exclusion criteria: * Patients with coagulopathy (INR \> 1.5). * Severe refractory hypoxemia or type 2 respiratory failure (hypoventilation with hypercapnia). * Severe pulmonary hypertension (PASP \> 55 mmHg). * Hemodynamic instability. * Lung collapse \> 2 months duration.

    Procedure: Cryotherapy for Bronchoscopic Management of Central Airway Obstruction

Interventions

  • ProcedureCryotherapy for Bronchoscopic Management of Central Airway Obstruction

    Intervention Protocol (Therapeutic Bronchoscopy) 1. General Preparation * Anesthesia: This procedure will be performed under local anesthesia . * Equipment: A flexible bronchoscope (e.g., Pentax EBK-3000) with a 3.2 mm working channel. * Pre-medication: Intramuscular atropine (0.5 mg) to reduce secretions and prevent vasovagal reflexes and nebulized lidocaine. * Mapping: Determination of the location and degree of obstruction according to the Freitag et al \[8\]. scheme. 3\. Specific Techniques Bronchoscopic Cryotherapy (ERBOKRYO CA): In a well-equipped room with monitoring of blood pressure ,heart rate ,respiratory rate and oxygen saturation. * Mechanism: Utilizing the Joule-Thompson effect, where high-pressure (60 bar) carbon dioxide as a cooling agent rapidly expands at the probe tip due to the difference with the atmospheric pressure, reducing the temperature to approximately - 78 °C \[9\]. * Application: Procedures will be conducted under local aesthesia

06

What researchers measure

Primary outcomes

  1. percentage of patients achieving central airway recanalization.

    Successful airway recanalization following therapeutic bronchoscopic cryotherapy for central airway obstruction (CAO), defined according to the Freitag et al. and Hussein et al. criteria.

    Time frame: Follow up after 3 months

Secondary outcomes

  1. Change in Dyspnea Severity.

    Change from baseline in dyspnea evaluated using the modified Medical Research Council (mMRC) dyspnea scale (score range 0 to 4, where higher scores indicate worse dyspnea).

    Time frame: baseline and at 3 months follow up

  2. Change in Cough Score

    Change from baseline according to walsh cough score

    Time frame: baseline and at 3 months follow up period

  3. Change in Hemoptysis Score

    Change from baseline according to morice hemoptysis score

    Time frame: baseline and at 3 months follow up period

  4. Incidence of Minor and Major Peri-procedural Complications

    Number of participants with treatment-related adverse events and complications, categorized by severity using the Common Terminology Criteria for Adverse Events (CTCAE) framework.

    Time frame: Within 24 hours post-procedure

  5. Rate of Airway Re-obstruction and CAO-related Re-hospitalization

    Percentage of patients experiencing symptomatic airway re-obstruction or requiring re-hospitalization related to central airway obstruction (CAO).

    Time frame: up to 3 months

  6. 1-Year Overall Survival (OS) Rate

    Percentage of participants alive at 1 year following the bronchoscopic cryotherapy intervention.

    Time frame: 1 year

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.

Of 36 non-industry interventional studies with no phase under Airway Obstruction, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 44 studies reached it within 16 months; a quarter within 3 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 18, 2026
StartEst.
Nov 10, 2026
Primary completionEst.
Nov 10, 2027
CompletionEst.
Nov 10, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945574
Lead sponsor
Assiut University
Responsible party
Ebtesam Adel Hammad Askar (Assistant. Lecturer- Chest department- Faculty of Medicine, Assiut University) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Nov 10, 2027 (estimated)
Completion
Nov 10, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Ebtesam Adel Hammad Askar, Assistant Lecturer
Contact
ebtesam6569@gmail.com
+2001012089691

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion